文献速递神经肿瘤

大体积脑膜瘤单次与多分次大分割立体定向放射外科治疗后的毒性反应比较

Posttreatment toxicity following single-fraction versus multifraction hypofractionated stereotactic radiosurgery for larger meningiomas.
PubMed 文献 · J Neurosurg · 2025-08-08

该单中心回顾性研究分析了121例单次SRS和51例多分次hSRS治疗的大于2cm脑膜瘤病例,限定肿瘤体积在2.7至49.3cm³重叠范围。结果显示两组治疗后CTCAE≥2级毒性无显著差异,但hSRS组局部无失败率更高。提示对较大脑膜瘤,多分次hSRS可能有助于限制治疗后水肿和毒性风险,同时维持可接受的局部控制。

要点

  • 对于大于2cm的脑膜瘤,多分次hSRS与单次SRS在CTCAE≥2级毒性方面无显著差异。
  • 多分次hSRS组局部无失败率在1、3、5年分别为96.0%、91.0%、91.0%,高于单次SRS组。
  • 多分次hSRS可能有助于限制较大脑膜瘤治疗后水肿和毒性风险。

核心结论

  • 在控制肿瘤体积后,尽管hSRS组治疗剂量更高,两组治疗后毒性无显著差异,且hSRS组局部无失败率改善。
  • 对较大脑膜瘤,多分次hSRS可能有助于限制治疗后水肿和毒性风险,同时维持可接受的局部无失败率。

研究设计与样本

  • 单中心回顾性分析,使用Wake Forest大学放射肿瘤科前瞻性管理的伽玛刀数据库。
  • 纳入121例单次SRS病例(中位剂量12 Gy)和51例多分次hSRS病例(中位剂量20 Gy),肿瘤体积限定在2.7至49.3 cm³重叠范围。

主要发现

  • 单次SRS组1、3、5年局部无失败率分别为87.0%、79.0%、63.6%;hSRS组分别为96.0%、91.0%、91.0%。
  • 单次SRS组1、3、5年总生存率分别为97.5%、79.7%、72.6%;hSRS组分别为85.5%、80.9%、76.4%。

临床怎么用

  • 对于体积较大的脑膜瘤,多分次hSRS可作为单次SRS的替代方案,以限制治疗后水肿和毒性风险。
  • 临床决策时需结合肿瘤体积和剂量参数,个体化选择单次或分次SRS策略。

局限性

  • 单中心回顾性研究,样本量有限,可能存在选择偏倚。
  • 分析仅限肿瘤体积2.7至49.3 cm³的重叠范围,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stereotactic radiosurgery (SRS) has been used to manage patients with intracranial meningioma with contraindications to resection. Limitations to SRS traditionally include tumors > 3 cm due to the risk of posttreatment toxicity. Hypofractionated SRS (hSRS) has been proposed as an alternative for tumors exceeding volume constraints for single-fraction SRS, although how hypofractionation affects the volume versus toxicity relationship has not been reported. Thus, the authors conducted a single-institution retrospective analysis of the medical records of patients receiving single-fraction SRS or multifraction hSRS for large (> 2 cm) meningiomas to assess the effect of hypofractionation on the likelihood of posttreatment toxicity. METHODS: Patients were identified using the Wake Forest University Department of Radiation Oncology prospectively administered Gamma Knife database. Patients were included if they had single-fraction SRS or multifraction hSRS for a diagnosis of meningioma that was > 2 cm. Analysis was limited to tumor volumes between 2.7 and 49.3 cm3, the overlapping range shared by those undergoing hSRS or SRS. Electronic medical records were used to determine patient and tumor characteristics and clinical outcomes. RESULTS: A total of 121 SRS cases with a median dose of 12 Gy and 51 hSRS cases with a median dose of 20 Gy with tumor volumes between 2.7 and 49.3 cm3 were identified and included in the analysis. The probabilities of freedom from local failure at 1, 3, and 5 years were 87.0%, 79.0%, and 63.6%, respectively, for patients receiving single-fraction SRS and 96.0%, 91.0%, and 91.0%, respectively, for patients receiving multifraction hSRS. The probabilities of overall survival at 1, 3, and 5 years were 97.5%, 79.7%, and 72.6%, respectively, for patients receiving single-fraction SRS and 85.5%, 80.9%, and 76.4%, respectively, for patients receiving multifraction hSRS. Eighteen (14.9%) of 121 patients receiving single-fraction SRS experienced Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2 toxicity, and 12 (23.5%) of 51 patients receiving multifraction hSRS experienced CTCAE grade ≥ 2 toxicity. CONCLUSIONS: When controlling for tumor volume, despite higher treatment doses in the hSRS group relative to the SRS group, posttreatment toxicity was not significantly different between the groups, and freedom from local failure was improved in the hSRS group. For patients with larger meningiomas, multifraction hSRS may help to limit the risk of posttreatment edema and toxicity, while maintaining acceptable freedom from local failure.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Smith EC, Calafiore RL, Christensen RR, et al. Posttreatment toxicity following single-fraction versus multifraction hypofractionated stereotactic radiosurgery for larger meningiomas. J Neurosurg. 2025. PMID: 40779801. doi:10.3171/2025.4.JNS242824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。